These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34579870)

  • 1. Spectral-Domain OCT Imaging of Lipemia Retinalis.
    Teoh CS; Yuen YS
    Ophthalmol Retina; 2021 Oct; 5(10):1016. PubMed ID: 34579870
    [No Abstract]   [Full Text] [Related]  

  • 2. Focus on fenofibrate.
    Brown WV
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():31-40. PubMed ID: 3134383
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of fenofibrate and clofibrate hypolipidemic effects.
    Daubresse JC
    Acta Clin Belg; 1980; 35(4):227-32. PubMed ID: 7015771
    [No Abstract]   [Full Text] [Related]  

  • 4. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipemia retinalis following systemic steroids for neurocysticercosis in a juvenile diabetic.
    Chahande S; Murthy R
    Indian J Pediatr; 2015 Mar; 82(3):298-9. PubMed ID: 25186570
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
    Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
    de Luis DA; Bachiller P; Aller R
    Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 12. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipemia retinalis of prematurity.
    Ikesugi K; Doi M; Nishi A; Uji Y
    Arch Ophthalmol; 1996 Oct; 114(10):1283-4. PubMed ID: 8859097
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lipemia retinalis: contribution of ultra-widefield imaging and spectral domain OCT].
    Prod'hom S; Weinberger A; Thumann G; Malclès A
    J Fr Ophtalmol; 2019 Oct; 42(8):940-943. PubMed ID: 31182253
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
    Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
    J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
    J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
    Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
    Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
    Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
    J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.